Maravai LifeSciences Investor Presentation 2023

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Maravai LifeSciences presented its 2023 investor outlook covering nucleic acid production, biologics safety testing, and cell and gene therapy capabilities. The presentation discusses COVID-19 revenue dynamics, customer growth strategies, facility investments, and the Alphazyme acquisition to strengthen mRNA and advanced therapy manufacturing services.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Maravai LifeSciences

View all →

presentation

FINAL_Maravai_1Q23_Earnings_call_slides_5.8.23_updated_5.9.23_updatedAug23

presentation

Similar investor_presentations from other companies

Browse all →

I-Mab Biopharma April 2024 Investor Presentation

investor_presentation

25 Pages

I-Mab Biopharma

Georgia Capital PLC 1H18 Results Investor Presentation 2018

investor_presentation